Enliven Therapeutics Upsizes Public Offering to $400M, Shares Climb on Strong Demand
ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (3.7× avg).
Summary
Enliven Therapeutics priced an upsized public offering, raising $400 million through common stock and pre-funded warrants at $37.50 per share. The stock climbed 15% to $46.37 following the announcement. This significant capital raise, which was upsized from an initial $250 million and then $333.75 million, follows the company's recent positive Phase 1 data for its lead drug ELVN-001 and FDA agreement for its next trial phase. The strong investor demand for this dilutive offering, evidenced by the upsize and stock price increase, reflects high confidence in the company's pipeline and extended cash runway. The offering is expected to close around Monday.
At the time of this announcement, ELVN was trading at $46.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $14.79 to $48.53. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.